Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.42 |
| ▸ | CTSL | P07711 | 8/20 | 0.37 |
| ▸ | CTSB | P07858 | 7/20 | 0.37 |
| ▸ | CTSH | P09668 | 5/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921684 | 1.00 | CTSK (0.42) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL9921685 | 0.91 | — | — | |
| SCHEMBL9921706 | 0.82 | PIK3CD (0.36) | CTSK | |
| SCHEMBL9921960 | 0.80 | CPN1 (0.42) | CTSK | |
| SCHEMBL6564282 | 0.79 | CYP1A2 (0.34) | CTSKCTSLCTSBCTSH | |
| SCHEMBL9918284 | 0.79 | CTSK (0.41) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL9918255 | 0.79 | CTSK (0.41) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL9918254 | 0.78 | CTSK (0.43) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL9918186 | 0.78 | CTSK (0.43) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL2347849 | 0.78 | CYP1A2 (0.38) | CTSKCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CTSK 2774/4885CTSL 4699/4885CTSB 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.